Analysts rate Relmada Therapeutics Inc. (RLMD:NSD) with a Buy rating and a $7 target

Jefferies Financial LLC rates Relmada stock as Hold.

Based on the Relmada Therapeutics Stock Forecast from 5 analysts, the average analyst RLMD stock price target is USD 7.00 over the next 12 months. Relmada Therapeutics Inc’s average analyst rating is Buy. Stock Target Advisor’s own stock analysis of RLMD stock forecast is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, RLMD stock price was USD 6.48RLMD stock price has changed by -29.37% over the past week, -24.58% over the past month and -73.76% over the last year.

 

About Relmada Therapeutics Inc. (RLMD:NSD):

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

 

What we like:

High market capitalization

Relmada stock is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

RLMD stock has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.

 

What we don’t like:

High volatility

The total returns for Relmada stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

RLMD stock price is trading high compared to its peers median on a price to book value basis.

Negative cashflow

Relmada Therapeutics had negative total cash flow in the most recent four quarters.

Negative earnings

Relmada Therapeutics had negative total earnings in the most recent four quarters.

Negative free cash flow

Relmada Therapeutics had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

Relmada stock has shown below median earnings growth in the previous 5 years compared to its sector.